Inosine
1. Identity and Chemical Characterization
Inosine is a naturally occurring purine nucleoside with the chemical (IUPAC) name hypoxanthine 9-β-D-ribofuranoside.
It is formed when hypoxanthine (IUPAC name: 1,7-dihydropurin-6-one; molecular formula: C₅H₄N₄O) is linked by its N9 nitrogen to the C1 carbon of ribose.
The molecular formula of inosine itself is C₁₀H₁₂N₄O₅, with a molecular weight of approximately 268.23 g/mol.
Inosine is a nucleoside that is formed when hypoxanthine is attached to a ribose ring (also known as a ribofuranose) via a β-N9-glycosidic bond. It was discovered in 1965 in analysis of RNA transferase.
Inosine is commonly found in tRNAs and is essential for proper translation of the genetic code in wobble base pairs.
In the Anatomical Therapeutic Chemical (ATC) Classification System, inosine is classified as an antiviral.
It is closely related metabolically to adenosine; deamination of adenosines by specific RNA deaminases is the major biological mechanism for inosine generation, through a reaction that converts the 6-aminopurine ring of adenosine to a 6-oxopurine ring.
Natural Sources and Dietary Occurrence
Inosine is not an essential nutrient.
It is produced endogenously and is also found in a variety of foods.
Brewer's yeast and organ meats, such as liver and kidney, contain considerable amounts.
Inosine has also been found to be an important feed stimulant by itself or in combination with certain amino acids in some species of farmed fish.
Beyond food sources, inosine arises endogenously from the breakdown of adenosine and AMP within cellular purine metabolism.
Common Forms and Preparations
- Inosine is available in purified form as a dietary supplement, most commonly as oral capsules or tablets.
- Inosine monophosphate (IMP), a phosphorylated derivative, is a separate but related compound used in the food industry as a flavor enhancer.
- Inosine (chemical name: hypoxanthine 9-β-D-ribofuranoside) is an intermediary metabolite of purine metabolism. Inosine is available as an over-the-counter supplement for oral use.
- Intravenous formulations have historically been used in clinical and research settings, particularly in cardiac and neurological contexts.
2. Traditional and Historical Use
Inosine does not have a documented history of use in classical Western herbalism, traditional Chinese medicine, or Ayurveda in the same manner as plant-derived botanical supplements, because it is an endogenous biochemical rather than a botanical constituent. Its identification and deliberate therapeutic application is entirely a modern phenomenon rooted in twentieth-century biochemistry.
Inosine attracted attention as a performance-boosting dietary supplement in the 1970s.
This era saw the compound enter widespread use among athletes, particularly in the Soviet Union and Eastern Europe, where it was employed under the premise that increasing purine nucleoside availability could augment ATP synthesis, thereby improving muscular endurance and recovery. Soviet-era sports medicine incorporated inosine as part of broader metabolic support regimens for competitive athletes, including weightlifters and endurance competitors.
For many years, inosine was considered to be a simple metabolite of adenosine which was devoid of any cardiovascular effects.
In Eastern European clinical practice during the 1970s and 1980s, intravenous preparations of inosine were used in hospital settings for cardiac conditions, particularly post-ischemic recovery, based on the hypothesis that supplementing purine intermediates could accelerate myocardial energy restoration. These applications preceded the formal randomized controlled trial era, and the supporting evidence was primarily observational.
Inosine's reputation as an athletic performance enhancer led to its widespread marketing and use as a nutritional supplement.
By the 1990s, inosine had become a mainstream supplement in Western countries, sold in capsule form with claims primarily directed at athletes seeking enhanced aerobic performance and recovery. These claims, however, were not supported by subsequent rigorous clinical investigation.
3. Key Constituents, Biochemistry, and Mechanisms of Action
3.1 Role in Purine Metabolism
In extant organisms, molecular inosine serves as a key intermediate in purine metabolism and is a widespread component of various nucleic materials.
Purine nucleoside phosphorylase interconverts inosine and hypoxanthine.
Inosine is also an intermediate in a chain of purine nucleotide reactions required for muscle movements.
Inosine monophosphate is oxidized by the enzyme inosine monophosphate dehydrogenase, yielding xanthosine monophosphate, a key precursor in purine metabolism.
The downstream fate of inosine in human metabolism is particularly significant: after ingestion, inosine is catabolized through hypoxanthine and xanthine, ultimately yielding uric acid (urate). This metabolic cascade is central to many of inosine's proposed therapeutic applications.
3.2 Energy Metabolism
Inosine plays many roles, one of which is helping to make ATP (adenosine triphosphate), the body's main form of usable energy.
At the cellular level, inosine serves as an alternative carbon source, fueling the tricarboxylic acid (TCA) cycle and sustaining ATP production under conditions of glucose deprivation or hypoxia.
3.3 RNA Function and Wobble Base Pairing
In RNAs, inosine plays two major functional roles. Inosine at the wobble position (I₃₄) of tRNAs allows the translation of C-, A-, and U-ended codons. This expands the repertoire of triplets that the modified tRNA can recognize and, in doing so, profoundly modifies the balance between codon usage and tRNA abundance in the organisms where the modification is abundant.
In mRNAs, on the other hand, inosine changes the informational content of transcripts, and it can modify the three-dimensional structure of double-stranded regions, thus influencing interactions with RNA-binding proteins.
3.4 Purinergic Signaling via Adenosine Receptors
Beyond metabolism, inosine functions as a purinergic signaling molecule, engaging adenosine receptors to control obesity and regulate inflammation and neuroprotection.
Adenosine is rapidly converted to inosine by adenosine deaminase (ADA) expressed on the cell surface. Adenosine and inosine signal through multiple adenosine receptor subtypes (A1R, A2AR, A2BR, and A3R), with A2AR and A2BR playing a predominant role in the suppression of anti-tumor immune cell responses.
Notably, inosine has a unique signaling bias upon A2AR binding, favoring the ERK1/2 pathway to PKA stimulation, and, relative to adenosine, inosine is approximately four orders of magnitude less potent at A2AR.
3.5 GABAA Receptor Interaction
Inosine is a natural ligand for the benzodiazepine binding site on the GABAA receptor.
This interaction has attracted interest in the context of anxiety and neuroprotection research, though the physiological significance and clinical applicability of this mechanism in human supplementation remain areas of ongoing inquiry.
3.6 Conversion to Uric Acid (Antioxidant Mechanism)
After ingestion, inosine is metabolized into uric acid, which has been suggested to be a natural antioxidant and peroxynitrite scavenger with potential benefits to patients with multiple sclerosis (MS).
Urate accounts for 60% plasma antioxidant capacity and acts as a scavenger of free radicals, exerting neuroprotective effects on animal models of brain/spinal cord injury, multiple sclerosis, and stroke.
This urate-elevating property is the basis for most modern clinical investigation of inosine.
3.7 RNA Editing (A-to-I Editing)
Inosine contributes to post-transcriptional regulation as a nucleoside through adenosine-to-inosine RNA editing.
This process, catalyzed by ADAR (adenosine deaminase acting on RNA) enzymes, recodes specific mRNA sites and is thought to contribute to transcriptomic diversity in the nervous system and immune system.
3.8 Axonal Growth Promotion
The purine nucleoside inosine has previously been shown to induce neurons to express a set of growth-associated proteins and to extend axons in culture and in vivo.
The molecular basis involves activation of specific intracellular signaling pathways that promote axon elongation; this has been most extensively studied in the context of corticospinal tract injury.
4. Scientific Evidence by Area of Application
4.1 Athletic Performance
The use of inosine as an ergogenic (performance-enhancing) aid represented its first major commercial application and has been the subject of several controlled human trials.
Three exercise physiology studies of oral inosine on athletic performance in humans have been published. All three reported that multi-gram doses (up to 10 g/day) were well tolerated short-term (up to 10 days), but had no demonstrable benefit on athletic performance.
One such study examined inosine at doses of 10.0 g/day (5.0 g twice daily) for 10 days, which was associated with a rise in serum urate from 7.3 (baseline) to 13.9 mg/dL. No adverse events were reported; however the sample size was small: n=7 healthy fit subjects (all active cyclists).
Another widely cited trial used 5.0 g/day of inosine for 5 days in trained cyclists. A third study by McNaughton et al. (1999) similarly found that prolonged inosine supplementation does not appear to improve aerobic performance and short-term power production during cycling and may actually have an ergolytic effect under some test conditions. Inosine supplementation has no effect on aerobic or anaerobic cycling performance.
An earlier trial by Dragan et al. (1994) in elite weightlifters used a dose of 1.5 g inosine (3 × 500 mg) daily for 6 weeks in 14 top weightlifters. Six weeks inosine treatment induced significant changes for serum lipids and FFA (increase), urine mucoproteins (decrease), and evoked muscular potential. However, this study has methodological limitations and its results have not been independently replicated with rigorous endpoints.
Despite lack of clinical evidence that it improves muscle development, inosine remains an ingredient in some fitness supplements.
Subsequent studies in humans suggest that inosine supplementation has no effect on athletic performance.
Evidence strength: The evidence for athletic performance enhancement is consistently negative in controlled human trials. The hypothesis lacks support at clinically tested doses.
4.2 Parkinson's Disease
The rationale for inosine in Parkinson's disease (PD) rests on the observation that elevated urate is epidemiologically associated with reduced PD risk and slower progression. Urate is the enzymatic end product of purine metabolism in humans and other hominoids. The resulting urate elevation may have been advantageous, as urate constitutes the main antioxidant circulating in human plasma. Oxidative damage is thought to play a role in the underlying dopaminergic neuron degeneration of Parkinson's disease, and urate protects dopaminergic neurons in cellular and animal models of PD.
The SURE-PD Phase II trial was the first large clinical study to formally test this approach. The objective was to determine the safety, tolerability, and urate-elevating capability of the urate precursor inosine in early PD. The Safety of Urate Elevation in PD (SURE-PD) study was a randomized, double-blind, placebo-controlled, dose-ranging trial of inosine that enrolled participants from 2009 to 2011 and followed them for up to 25 months at outpatient visits to 17 credentialed clinical study sites of the Parkinson Study Group across the United States.
Dosing in SURE-PD was gradual: treatment was initiated with 1 capsule (500 mg of inosine per capsule) taken 2 times daily for 2 weeks. After the 2- and 4-week visits, participants received up to 2 capsules 2 to 3 times daily, as algorithmically determined by serum urate concentration and treatment group assignment. Target urate levels were achieved between 2 and 4 weeks after initiation of inosine treatment.
The SURE-PD trial demonstrated that the urate precursor molecule inosine taken by mouth was generally very well-tolerated, safe, and capable of substantially increasing levels of urate in blood and around the brain over months to years.
Secondary analyses demonstrated non-futility of inosine treatment for slowing disability.
These positive safety and feasibility findings led to the pivotal SURE-PD3 Phase III trial. SURE-PD3 was a randomized, double-blind, placebo-controlled trial of urate-elevating inosine treatment to slow clinical decline in early PD.
The results of the inosine clinical trial were published and unfortunately it was reported that daily treatment with inosine for 2 years had no impact on slowing the course of Parkinson's in terms of motor and non-motor symptoms. The treatment was found to be very safe and well tolerated, but it did not have a disease-modifying effect.
Evidence strength: Phase III trial evidence (SURE-PD3) is negative for disease modification, despite promising Phase II signals and strong preclinical rationale. Inosine reliably elevates urate levels and is well tolerated, but the primary endpoint of slowing PD progression was not met.
4.3 Multiple Sclerosis (MS)
The rationale for inosine in MS is similar to that in PD: uric acid could act as a natural peroxynitrite scavenger with antioxidant properties. It has been proposed that hyperuricemia might protect against multiple sclerosis.
An early pilot randomized double-blind trial by Markowitz et al. (2009) investigated inosine in 16 patients with relapsing–remitting MS. Oral administration of inosine was used to raise serum levels of the natural peroxynitrite scavenger uric acid in 16 patients with RRMS during a 1-year randomized, double-blind trial. The endpoints studied were relapse rate, disability assessed by the Kurtzke Expanded Disability Status Scale (EDSS), MRI, and analysis of serum levels of nitrotyrosine, and oxidative and proinflammatory markers. Increased serum uric acid levels correlated with a significant decrease in the number of gadolinium-enhanced lesions and improved EDSS.
The ASIIMS (Association of Inosine and Interferon beta in relapsing-remitting Multiple Sclerosis) trial combined inosine with interferon beta-1a. This has been explored in 3 small randomized clinical trials in relapsing-remitting MS using inosine, an oral precursor of urate, which increases serum levels.
A subsequent double-blind trial by Muñoz García et al. (2015) enrolled patients with relapsing-remitting MS. Patients with relapsing-remitting MS starting treatment with interferon beta-1a 44 µg sc 3/week were randomly assigned to receive either inosine 3 g/day or placebo in a double-blind manner. Follow-up was 12 months. Outcome measures were adverse events and uric acid laboratory results. The secondary endpoint was clinical and radiological activity of MS. Relapse rates, percentage of patients without relapses, and progression to secondary MS were assessed. Thirty-six patients were included.
Two patients in the inosine group showed uric acid serum levels above 10 mg/mL, and symptoms derived from renal colic not leading to hospital admission. Ten additional patients had asymptomatic hyperuricemia (above 7 mg).
Although randomized clinical trials would be ideal to provide evidence for or against a causal role for urate in MS, the few that have been performed have focused on disease outcomes among patients with MS rather than testing the proposed preventive effects. Such a trial would require prohibitively large sample sizes and is probably not feasible. Therefore, the role of urate in the risk of developing MS remains unclear.
Evidence strength: Preliminary and limited. Only small trials (the largest with 36 patients) have been completed. Results are mixed, and no adequately powered Phase III trial has been conducted in MS. Findings should be considered hypothesis-generating only.
4.4 Stroke and Neurological Injury
Animal studies have demonstrated that inosine promotes neuronal rewiring after brain injury through a distinct mechanism from its antioxidant/urate-elevating effects. The purine nucleoside inosine has previously been shown to induce neurons to express a set of growth-associated proteins and to extend axons in culture and in vivo. In adult rats with unilateral cortical infarcts, inosine stimulated neurons on the undamaged side of the brain to extend new projections to denervated areas of the midbrain and spinal cord. This growth was paralleled by improved performance on several behavioral measures.
In a rodent spinal cord injury model, following dorsal hemisections of the spinal cord that sever the corticospinal tract, inosine-treated animals performed far better than controls on tests of sensorimotor integration and general locomotion. These improvements correlated with increased sprouting of serotonergic (raphespinal) projections distal to the injury site and CST axons rostral to this site.
More recent animal work has investigated anti-inflammatory mechanisms: inosine is neuroprotective by reducing inflammasome activation and altering microglial polarization towards the M2 phenotype.
In a rat model of ischemic stroke, inosine administration at 1 hour post-ischemic stroke decreased infarct size, neurodeficit score, and improved motor coordination.
Several clinical studies suggest that the acute infusion of uric acid (or its precursor inosine) may confer some benefits in neurological disorders such as Parkinson's disease and acute ischemic stroke.
However, to date no large-scale, definitive RCT in human stroke has been completed using inosine as the primary intervention.
Evidence strength: Predominantly animal/preclinical data. The axonal sprouting mechanism is well-documented in rodent models but has not been demonstrated in human clinical trials. Evidence in human stroke remains preliminary.
4.5 Amyotrophic Lateral Sclerosis (ALS)
Given the rationale that urate is neuroprotective and may be low in ALS patients, inosine has been explored as a urate-elevating strategy in this disease. Urate, the metabolite of inosine, is an endogenous antioxidant and potential neuroprotectant. Its level is lower in patients with ALS, and a high urate level is associated with improved survival.
Inosine supplementation in vitro was found to increase glycolytic flux, bioenergetic capacity, and survival of motor neurons by reducing induced astrocyte-mediated toxicity.
In a Phase 2 study, inosine was well tolerated by patients. Inosine is an endogenous antioxidant that may protect against oxidative stress.
Evidence strength: Very preliminary. Only small Phase 2 feasibility/safety trials have been completed. There is a plausible mechanistic rationale, but clinical efficacy has not been established.
4.6 Cardiovascular Disease
Interest in inosine for heart disease predates its neurological applications. The inotropic and coronary vasodilator effects of inosine are not associated with any modification of the chronotropic function. Inosine is not arrhythmogenic, even at high doses. Furthermore, it does not affect atrioventricular conduction. It has been demonstrated that inosine is capable of antagonizing ouabain-induced arrhythmias. Various clinical studies confirm the positive inotropic action of inosine, without any alteration in post-load, pre-load, or heart rate. The positive inotropic action of inosine can therefore be considered to be selective. Together with these hemodynamic effects, it has been shown that the addition of inosine to cardioplegic solutions improves the functional recovery of the myocardium, by increasing the quantity of energy-rich phosphates.
In a preclinical model, prophylactic administration of the probiotic Bifidobacterium infantis exhibited cardioprotective effects against myocardial ischemia–reperfusion (I/R) injury, which was recapitulated by its metabolite inosine. Inosine suppressed cardiac inflammation by reducing the production of pro-inflammatory cytokines and decreasing the numbers of dendritic cells and natural killer cells after I/R. Additionally, inosine attenuated cell death by serving as an alternative carbon source for ATP generation through the purine salvage pathway in stressed myocytes.
Evidence strength: Much of the cardiovascular evidence is from preclinical studies or small, older clinical investigations, often using intravenous routes not applicable to oral supplementation. The most rigorous modern data (SURE-PD3, MS trials) monitor cardiovascular endpoints as safety outcomes and do not confirm adverse or favorable cardiovascular effects at oral supplementation doses used in those trials.
4.7 Immunomodulation and Cancer Immunotherapy
Knowledge of inosine metabolism has led to advances in immunotherapy in recent decades.
Inosine's role in purinergic signaling at adenosine receptors has made it a subject of significant research in tumor immunology.
Adenosine is rapidly converted to inosine by adenosine deaminase expressed on the cell surface. Adenosine and inosine signal through multiple adenosine receptor subtypes (A1R, A2AR, A2BR, and A3R), with A2AR and A2BR playing a predominant role in the suppression of anti-tumor immune cell responses.
Interestingly, the role of inosine in cancer immunotherapy is context-dependent and paradoxical: supplementation with inosine enhanced the antitumor efficacy of immune checkpoint inhibitors and ACT in multiple solid tumor models. Inosine has a unique signaling bias upon A2AR binding, favoring the ERK1/2 pathway to PKA stimulation, and relative to adenosine, inosine is approximately four orders of magnitude less potent at A2AR, which may account for its differing effect on immunotherapies.
Additionally, intracellularly, inosine serves as an alternative carbon source, fueling the tricarboxylic acid (TCA) cycle and sustaining ATP production under conditions of glucose deprivation or hypoxia.
Research published in Nature Metabolism (2020) demonstrated that inosine can fuel CD8+ T-cell function when glucose is restricted, which has implications for immune responses in nutrient-deprived tumor microenvironments.
Evidence strength: Largely preclinical (cell culture and animal models). The immunomodulatory mechanisms are scientifically well-characterized, but clinical translation to human cancer immunotherapy using oral inosine supplementation is not yet established through RCTs.
4.8 Diabetic Neuropathy
A multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER) assessed the efficacy and safety of a combined metabolic medication containing inosine, nicotinamide, riboflavin, and succinic acid for the treatment of diabetic neuropathy.
Because this trial used a multi-component formulation, the specific contribution of inosine cannot be isolated from these findings, and attributing outcomes to inosine alone would be scientifically inappropriate.
Evidence strength: Preliminary; the use of a combination product prevents isolation of inosine's contribution.
5. Body Systems and Health Areas
- Nervous system: Neuroprotection via urate antioxidant activity; axonal sprouting and rewiring in injury models; GABAA receptor modulation; A-to-I RNA editing in neuronal transcripts.
- Cardiovascular system: Historical use as a cardioprotective and inotropic agent; preclinical evidence of cardioprotection in ischemia-reperfusion models.
- Immune system: Purinergic signaling at adenosine receptors modulating T-cell activity; alternative energy substrate for CD8+ T cells; role in tumor microenvironment immunosuppression and immunotherapy enhancement.
- Musculoskeletal system: Proposed (but not clinically validated) role in ATP replenishment for muscle performance.
- Metabolic/cellular energy: Key intermediate in purine salvage and de novo synthesis pathways; TCA cycle fuel under hypoxia.
- Renal system: Significant safety consideration — elevated urate from inosine catabolism poses risk of uric acid urolithiasis and potential gout.
- Molecular biology/genetics: Essential for accurate tRNA wobble base pairing and mRNA recoding via ADAR-mediated A-to-I editing.
6. Dosage Forms and Reported Dosages
The following dosages are reported in the published scientific literature; they represent the doses used in specific studies and should not be taken as general prescriptive guidance.
- Sports performance studies:
- 10.0 g/day (5.0 g twice daily) for 10 days — used in a cycling performance trial in 7 healthy cyclists.
- 5.0 g/day for 5 days — used in an aerobic and anaerobic cycling performance trial.
- 1.5 g daily (3 × 500 mg) for 6 weeks — used in a study of elite weightlifters.
- Parkinson's disease (SURE-PD Phase II):
Treatment was initiated with 1 capsule (500 mg of inosine per capsule) taken 2 times daily for 2 weeks, after which participants received up to 2 capsules 2 to 3 times daily, as algorithmically determined by serum urate concentration and treatment group assignment.
Two target serum urate ranges were studied: mild (6.1–7.0 mg/dL) and moderate (7.1–8.0 mg/dL) elevation.
- Multiple sclerosis trials:
Patients with relapsing-remitting MS received inosine 3 g/day or placebo in a double-blind manner.
- General supplement use:
When used as a sports supplement, a typical dosage of inosine is five to six grams daily.
7. Safety, Adverse Effects, and Drug Interactions
7.1 General Tolerability
Considerable non-clinical human experience on inosine has been gained from its widespread use as a nutritional supplement. In this context, inosine has been considered safe, although exposures are variable in size and poorly documented.
Multi-year clinical trials of oral inosine in multiple sclerosis and Parkinson's disease at comparable doses have been conducted. In these studies, inosine at doses sufficient to chronically elevate urate was well tolerated, with the most consistent adverse event being the rare development of uric acid urolithiasis.
7.2 Hyperuricemia
The primary pharmacological consequence of inosine supplementation is elevation of serum uric acid (urate). Potential side effects of inosine relate to the resulting elevated urate (uric acid) levels (hyperuricemia). Hyperuricemia has been linked to gout (which generally develops in people with serum urate concentrations above 8 mg/dL) and to the formation of urate stones in the kidneys or ureters (urolithiasis).
In most uric acid stone formers the primary pathophysiologic defect is an excessively acidic urine pH rather than hyperuricemia.
This is an important distinction for risk stratification.
7.3 Urolithiasis
The most consistent adverse event was the development of uric acid urolithiasis. In the PD study, where people with acidic urine were excluded and target urate levels did not exceed 8 mg/dL, the prevalence of urolithiasis was 6%.
A preliminary double-blind crossover study that enrolled seven participants suggests that high doses of inosine (5,000 to 10,000 milligrams per day for five to ten days) may increase the risk of uric acid-related problems, such as gout or kidney stones.
7.4 Gout and Cardiovascular Risk
High urate levels have also been associated with high blood pressure and increased risk for cardiovascular events. However, whether a causal relationship between high urate and cardiovascular disease exists is unclear.
There were no reports of gout and no excess cardiovascular events relative to placebo in the major MS and PD clinical trials.
7.5 High-Dose Exposure
At 10.0 g/day for 10 days, serum urate rose from 7.3 to 13.9 mg/dL. No adverse events were reported in this small short-term study (n=7).
The MS trial by Muñoz García et al. noted that two patients in the inosine group showed uric acid serum levels above 10 mg/mL and symptoms derived from renal colic not leading to hospital admission, while ten additional patients had asymptomatic hyperuricemia above 7 mg.
7.6 Special Populations
Individuals with gout should avoid inosine supplements, as it worsens the condition. The safety of inosine for young children, pregnant or nursing women, or those with serious liver or kidney disease has not been established.
7.7 Drug Interactions
Drugs that affect uric acid metabolism, such as allopurinol (used to treat gout), may interact with inosine. Allopurinol decreases uric acid levels by inhibiting xanthine oxidase, an enzyme involved in purine metabolism. Using inosine in conjunction with allopurinol could lead to unpredictable changes in uric acid levels.
Inosine increases levels of uric acid. High levels of uric acid might make gout worse. Taking inosine along with anti-gout drugs might reduce the effects of these drugs.
7.8 Blood Pressure
One dedicated study monitored blood pressure across a 1-year inosine trial in 16 MS patients and reported no significant elevation of blood pressure despite sustained elevation of serum urate levels. The role of uric acid in human physiology is subject to controversy — either it is an important radical scavenger, a mostly neutral waste metabolic product that may cause gout and kidney stones if elevated, or it is involved in the causation of hypertension, vascular, and renal diseases.
8. Summary of Evidence Strength
- Athletic performance: Multiple controlled human trials — consistently negative. No evidence of benefit.
- Parkinson's disease: Phase III RCT (SURE-PD3) — negative for disease modification; inosine reliably elevates urate and is well tolerated.
- Multiple sclerosis: Small RCTs only — preliminary, mixed, and underpowered. No definitive conclusions.
- Stroke / spinal cord injury: Primarily animal/in vitro data. Human clinical evidence is absent or very preliminary.
- ALS: Phase 2 feasibility data only. Efficacy unestablished.
- Cardiovascular protection: Preclinical and older small clinical data. Modern RCT evidence is lacking.
- Cancer immunotherapy: Preclinical mechanistic data. No established human supplementation protocol.
References
Go back